Traws Pharma, Inc. (NASDAQ:TRAW) Sees Large Growth in Short Interest

Traws Pharma, Inc. (NASDAQ:TRAW) was the target of a significant growth in short interest in December. As of December 31st, there was short interest totalling 141,900 shares, a growth of 1,956.5% from the December 15th total of 6,900 shares. Based on an average trading volume of 503,100 shares, the short-interest ratio is currently 0.3 days. Currently, 5.2% of the company’s stock are short sold.

Traws Pharma Price Performance

TRAW stock traded up $0.26 during mid-day trading on Wednesday, reaching $6.94. The company had a trading volume of 46,458 shares, compared to its average volume of 209,808. The company has a market capitalization of $21.00 million, a P/E ratio of -0.05 and a beta of 1.13. Traws Pharma has a 52 week low of $4.06 and a 52 week high of $27.50. The stock’s 50 day moving average is $6.49.

About Traws Pharma

Traws Pharma, Inc, a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza.